Stochastic optimal control of pre-exposure prophylaxis for HIV infection

被引:0
|
作者
Dordevic, Jasmina [1 ]
Dahl, Kristina Rognlien [2 ]
机构
[1] Univ Oslo, Fac Math & Nat Sci, N-0316 Oslo, Norway
[2] Univ Nis, Fac Sci & Math, Dept Math, Visegradska 33, Nish 18000, Serbia
关键词
stochastic differential equations; stochastic optimal control; HIV; pre-exposure prophylaxis; unconstrained control problem; constrained control problem; numerical examples; MAXIMUM PRINCIPLE; PREVENTION; HIV/AIDS; MODEL;
D O I
10.1093/imammb/dqac003
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aim of the paper is to apply the stochastic optimal control problem in order to optimize the number of individual which will have the pre-exposure prophylaxis (PReP) treatment in the stochastic model for HIV/AIDS with PReP. By using the stochastic maximum principle, we derive the stochastic optimal control of PReP for the unconstrained control problem. Furthermore, by combining the stochastic maximum principle with a version of the Lagrange multiplier method, we solve the PReP problem for two different types of budget constrains with a given constrain for the costs (possible of different kind, transportation, price of the treatment, etc.). Obtained results for the different percentage of the individuals who got the vaccine, as well as results for unconstrained and constrained problems, are illustrated by a numerical example.
引用
收藏
页码:197 / 225
页数:29
相关论文
共 50 条
  • [31] HIV Infection and Drug Resistance with Unsupervised Use of HIV Pre-Exposure Prophylaxis
    Volk, Jonathan E.
    Dong Phuong Nguyen
    Hare, C. Bradley
    Marcus, Julia L.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 (04) : 329 - 330
  • [32] Pre-exposure of Prophylaxis to Prevent HIV Infection - current Data and Recommendations
    Kuemmerle, T.
    Foewtkenheuer, G.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (44) : 2285 - 2288
  • [33] HIV Pre-exposure Prophylaxis: Characterization and Adherence of Users at Risk of Infection
    Paula de Franca, Francisco Alisson
    de Brito Passos, Ana Claudia
    Medeiros, Melissa Soares
    de Franca Fonteles, Marta Maria
    [J]. JOURNAL OF YOUNG PHARMACISTS, 2022, 14 (01) : 93 - 99
  • [34] Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection
    Tanuja N. Gengiah
    Atika Moosa
    Anushka Naidoo
    Leila E. Mansoor
    [J]. International Journal of Clinical Pharmacy, 2014, 36 : 70 - 85
  • [35] Primary HIV-1 infection in users of pre-exposure prophylaxis
    Ambrosioni, Juan
    Petit, Elisa
    Liegeon, Geoffroy
    Laguno, Montserrat
    Miro, Jose M.
    [J]. LANCET HIV, 2021, 8 (03): : e166 - e174
  • [36] The safety of HIV pre-exposure prophylaxis in the presence of hepatitis B infection
    Solomon, Marc M.
    Schechter, Mauro
    Liu, Albert Y.
    McMahan, Vanessa
    Guanira, Juan V.
    Hance, Robert J.
    Chariyalertsak, Suwat
    Mayer, Kenneth H.
    Grant, Robert M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [37] Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection
    El-Haddad, Amer
    Erlich, Deborah
    [J]. AMERICAN FAMILY PHYSICIAN, 2023, 107 (05) : 545 - 546
  • [38] Nurse's role in pharmacological pre-exposure prophylaxis of HIV infection
    Bartkowiak, Grzegorz
    Kryczka, Tomasz
    [J]. PIELEGNIARSTWO XXI WIEKU-NURSING IN THE 21 CENTURY, 2022, 21 (04): : 235 - 243
  • [39] Pre-exposure antiretroviral prophylaxis for human immunodeficiency virus (HIV) infection
    Castilla, J.
    [J]. MEDICINA DE FAMILIA-SEMERGEN, 2020, 46 (03): : 151 - 152
  • [40] Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection
    Gengiah, Tanuja N.
    Moosa, Atika
    Naidoo, Anushka
    Mansoor, Leila E.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (01) : 70 - 85